..and look at Healius, if you had picked this stock at the Covid lows of $1.815 in March 2020, you could have made 269% in just under 2 years when it peaked at $4.89.
..it surged on the back of huge pathology lab volumes from the Covid pandemic, but after the Covid crisis ended, so did the rally. But had you kept holding on, it has fallen -73% from the peak to $1.30 and -28% lower than the Covid low.
..when the catalyst driver for the rally is gone, so too must we part ways with the stock. And that's a huge lesson we all need to learn from any sector participation we involve ourselves in.
Pathology group Healius sinks to mega-loss of $636m
Simon Evans
Pathology company Healius has crashed to a bottomline loss of $636 million in the December half after a heavy writedown in its pathology division where goodwill has been slashed by $603 million.
Revenues were up 1.75 per cent to $849 million for the six months ended December 31.
Chief executive Maxine Jaquet said the company, in conjunction with the industry, is campaigning for indexation in the pathology industry from the federal government, which it has not had for 24 years.
She said in a high-inflation environment, Healius’ business is skewed toward the low-growth segment relying on GP volumes, and not the higher-growth segment stemming from patients visiting medical specialists.
